Forget the Headlines: Novo Nordisk's (NVO) 4.6% Dividend Yield Is the Real Story for Patient Investors
Key PointsEli Lilly's not the only GLP-1 game in town -- Novo Nordisk has an oral pill formulation.
Novo Nordisk, a Danish healthcare company, has captured headlines for its intriguing dividend yield. While its stock may pique investor interest, the company's dividend alone warrants attention. The payout currently stands at a substantial 4.6%, with an additional total shareholder yield of approximately 5.5% when considering share repurchases.
This is notably higher than the 1% yield offered by the S&P 500 index of America's largest companies. Furthermore, Novo Nordisk's dividend is a growing one, having increased significantly over the past few years, from $0.62 in 2019 to $1.85 per share in 2026. This upward trend is complemented by a relatively low payout ratio of just 45%, indicating that the company has ample capacity to maintain and potentially increase future dividends.
For investors seeking both income and growth, Novo Nordisk presents a compelling case. The shares appear reasonably valued at current levels, with a price-to-sales ratio of 3.5, which is considerably lower than the five-year average of 8.1. Additionally, the forward-looking price-to-earnings ratio stands at 12.3, nearly matching the five-year average of 11.9.
Novo Nordisk's business is also attractive, with a strong track record in treating diabetes and expanding into the weight-loss drug market. Their oral GLP-1 drug, in particular, has shown promise and is set to be available in over 20 markets. While the company faces competition and has encountered setbacks in clinical trials, its pipeline remains promising.
The Motley Fool's Stock Advisor, which has achieved an impressive average return of 790% compared to the S&P 500's 202%, recommends Novo Nordisk as one of the 10 best stocks to consider buying now.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.